Đánh giá tác dụng điều trị ban đầu của viên nang cứng DIDALA trên bệnh nhân đái tháo đường typ 2 mới được chẩn đoán

Abstract

This study was conducted to evaluate the efficacy of DIDALA monotherapy in reducing fasting plasma glucose and HbA1c levels and to assess its safety in newly diagnosed patients with type 2 diabetes mellitus at Hanoi General Hospital of Traditional Medicine. A controlled clinical interventional study with a before and after comparison design was conducted on seventy newly diagnosed patients with type 2 diabetes mellitus. Thirty-five patients in the study group received DIDALA (Folium Mori albae) at a dose of 3420 mg/day, while thirty-five patients in the control group received metformin at a dose of 1000mg/day for 12 weeks. After treatment, fasting plasma glucose in the study group decreased significantly from 8.2 ± 1.4 mmol/l to 7.5 ± 1.6 mmol/l, HbA1c decreased from 7.2 ± 1.0% to 6.6 ± 0.8% (p < 0.05). The efficacy of the study group was comparable to that of the control group (p > 0.05). No significant adverse effects were observed in clinical and paraclinical assessments. These findings suggest that DIDALA monotherapy effectively reduces fasting plasma glucose and HbA1c levels and is safe in newly diagnosed patients with type 2 diabetes mellitus.